<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Boceprevir</strong></td></tr><tr><th>Accession Number</th><td><strong>DB08873</strong></td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved</td></tr><tr><th>Description</th><td><p>Boceprevir is a direct acting protease inhibitor for the treatment of hepatitis C. It also has two isomers in which the S isomer is more active than the R-isomer. <span class="caps">FDA</span> approved on May 13, 2011.</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB08873/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB08873/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB08873.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB08873.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB08873.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB08873.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB08873.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB08873">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Salts</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Victrelis </td><td>Merck &amp; Co., Inc. </td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Categories</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>CAS number</th><td>394730-60-0</td></tr><tr><th>Weight</th><td>Average: 519.6767<br>Monoisotopic: 519.342069575</td></tr><tr><th>Chemical Formula</th><td>C<sub>27</sub>H<sub>45</sub>N<sub>5</sub>O<sub>5</sub></td></tr><tr><th>InChI Key</th><td>LHHCSNFAOIFYRV-DOVBMPENSA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C27H45N5O5/c1-25(2,3)20(30-24(37)31-26(4,5)6)23(36)32-13-15-17(27(15,7)8)18(32)22(35)29-16(19(33)21(28)34)12-14-10-9-11-14/h14-18,20H,9-13H2,1-8H3,(H2,28,34)(H,29,35)(H2,30,31,37)/t15-,16?,17-,18-,20+/m0/s1</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">3-{[(1R,2S,5S)-3-[(2S)-2-[(tert-butylcarbamoyl)amino]-3,3-dimethylbutanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2-yl]formamido}-4-cyclobutyl-2-oxobutanamide</div></td></tr><tr><th>SMILES</th><td><div class="wrap">[H][C@]12CN([C@H](C(=O)NC(CC3CCC3)C(=O)C(N)=O)[C@@]1([H])C2(C)C)C(=O)[C@@H](NC(=O)NC(C)(C)C)C(C)(C)C</div></td></tr><tr><th>Mass Spec</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Organic Acids and Derivatives</td></tr><tr><th>Class</th><td>Carboxylic Acids and Derivatives</td></tr><tr><th>Subclass</th><td>Amino Acids, Peptides, and Analogues</td></tr><tr><th>Direct parent</th><td>Hybrid Peptides</td></tr><tr><th>Alternative parents</th><td>N-carbamoyl-alpha Amino Acids and Derivatives; Alpha Amino Acid Amides; Piperidinecarboxylic Acids; N-Acylpiperidines; Pyrrolidinecarboxamides; Tertiary Carboxylic Acid Amides; Secondary Carboxylic Acid Amides; Tertiary Amines; Primary Carboxylic Acid Amides; Ketones; Enolates; Polyamines; Carboxylic Acids</td></tr><tr><th>Substituents</th><td>n-acyl-alpha amino acid or derivative; n-carbamoyl-alpha-amino acid or derivative; alpha-amino acid amide; alpha-amino acid or derivative; piperidinecarboxylic acid; n-acyl-piperidine; pyrrolidine carboxylic acid or derivative; pyrrolidine-2-carboxamide; piperidine; tertiary carboxylic acid amide; pyrrolidine; carboxamide group; ketone; secondary carboxylic acid amide; primary carboxylic acid amide; tertiary amine; carboxylic acid; enolate; polyamine; amine; carbonyl group; organonitrogen compound</td></tr><tr><th>Classification description</th><td>This compound belongs to the hybrid peptides. These are compounds containing at least two different types of amino acids (alpha, beta, gamma, delta).</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>Treatment of chronic hepatitis C genotype 1 in patients that have a compensated liver (as a result of liver diseases like cirrhosis) and are previously untreated or therapy with peginterferon alfa and ribavirin has failed. </td></tr><tr><th>Pharmacodynamics</th><td>Telaprevir is a direct-acting antiviral agent (DAA) against the hepatitis C virus.</td></tr><tr><th>Mechanism of action</th><td>Boceprevir inhibits replication of the hepatitis C virus by binding reversibly to nonstructural protein 3/4a (NS3 and NS4A respectively) serine protease. NS4A is a cofactor that works with NS3 for viral replication. </td></tr><tr><th>Absorption</th><td>Food increases exposure of boceprevir by up to 65% relative to fasting state. However, type of food and time of meal does not affect bioavailability of boceprevir and thus can be taken without regards to food.  
Tmax = 2 hours;
Time to steady state, three times a day dosing = 1 day;
Cmax, 400 mg single dose, healthy subject = 557 ng/mL;
AUC &#8734;, healthy subject = 2020 ng &#183; h/mL;</td></tr><tr><th>Volume of distribution</th><td><p>~722 L</p></td></tr><tr><th>Protein binding</th><td>~75%</td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>Hepatically metabolized by the aldo-ketoreductase pathway into inactive metabolites via reduction. To a lesser extent, CYP3A4 and CYP3A5 is also involved in the metabolism of boceprevir (oxidative process). </p></td></tr><tr><th>Route of elimination</th><td>Removed via feces (79%) and urine (9%) which suggest some degree of hepatic excretion. </td></tr><tr><th>Half life</th><td>Mean plasma half-life = 3.4 hours </td></tr><tr><th>Clearance</th><td><p>Mean total body clearance (Cl/F) = 161 L/h</p></td></tr><tr><th>Toxicity</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Affected organisms</th><td><ul><li>Hepatitis C virus, RSV and other RNA/DNA viruses</li></ul></td></tr><tr><th>Pathways</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              +
        </td>
        <td>0.6781</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              -
        </td>
        <td>0.8805</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              -
        </td>
        <td>0.6532</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Substrate
        </td>
        <td>0.8394</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Inhibitor
        </td>
        <td>0.671</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Inhibitor
        </td>
        <td>0.6377</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.8188</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.7965</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-substrate</td>
        <td>0.7996</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Substrate</td>
        <td>0.621</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.7987</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.7265</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.87</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.6908</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9659</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>Low CYP Inhibitory Promiscuity</td>
        <td>0.8434</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          Non AMES toxic 
        </td>
        <td>
            0.662
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.8555
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Ready biodegradable 
        </td>
        <td>
            0.5913
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          2.6263 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.9828
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Non-inhibitor 
        </td>
        <td>
            0.7092
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Packagers</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Capsule</td><td>Oral</td><td>200 mg</td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB00346">Alfuzosin</a></td><td>Boceprevir increases levels by affecting CYP3A4 metabolism. Concomitant therapy is contraindicated. </td></tr><tr><td><a href="/drugs/DB01076">Atorvastatin</a></td><td>Boceprevir increases the exposure of atorvastatin. Concomitant therapy should be closely monitored. </td></tr><tr><td><a href="/drugs/DB00564">Carbamazepine</a></td><td>Strong CYP3A4 inducers will decrease levels of boceprevir. Concomitant therapy is contraindicated. </td></tr><tr><td><a href="/drugs/DB00604">Cisapride</a></td><td>Boceprevir increases levels by affecting CYP3A4 metabolism. Concomitant therapy is contraindicated. </td></tr><tr><td><a href="/drugs/DB00872">Conivaptan</a></td><td>Boceprevir increases levels by affecting CYP3A4 metabolism. Concomitant therapy is contraindicated. </td></tr><tr><td><a href="/drugs/DB00320">Dihydroergotamine</a></td><td>Boceprevir increases levels by affecting CYP3A4 metabolism. Concomitant therapy is contraindicated. </td></tr><tr><td><a href="/drugs/DB01395">Drospirenone</a></td><td>Boceprevir increases levels by affecting CYP3A4 metabolism. Concomitant therapy is contraindicated. </td></tr><tr><td><a href="/drugs/DB06414">Etravirine</a></td><td>The exposure of etravirine decreases whereas boceprevir's exposure increased. Therapeutic implications of this observation is unknown. </td></tr><tr><td><a href="/drugs/DB01320">Fosphenytoin</a></td><td>Strong CYP3A4 inducers will decrease levels of boceprevir. Concomitant therapy is contraindicated. </td></tr><tr><td><a href="/drugs/DB08827">Lomitapide</a></td><td>Boceprevir increases levels of lomipatide by 27 folds by inhibiting CYP3A4 metabolism. Concomitant therapy of Boceprevir and strong CYP3A4 inhibitors (such as clarithromycin, conivaptan, indinavir, intraconazole, ketoconazole, lopinavir/ritonavir, mibefradil, nefazodone, nelfinavir, posaconazole, ritonavir, saquinavir, telaprevir, telithromycin, variconazole) with lomipatide is contraindicated. </td></tr><tr><td><a href="/drugs/DB00683">Midazolam</a></td><td>Boceprevir increases levels by affecting CYP3A4 metabolism. Concomitant therapy is contraindicated. </td></tr><tr><td><a href="/drugs/DB01174">Phenobarbital</a></td><td>Strong CYP3A4 inducers will decrease levels of boceprevir. Concomitant therapy is contraindicated. </td></tr><tr><td><a href="/drugs/DB00252">Phenytoin</a></td><td>Strong CYP3A4 inducers will decrease levels of boceprevir. Concomitant therapy is contraindicated. </td></tr><tr><td><a href="/drugs/DB01100">Pimozide</a></td><td>Boceprevir increases levels by affecting CYP3A4 metabolism. Concomitant therapy is contraindicated. </td></tr><tr><td><a href="/drugs/DB08901">Ponatinib</a></td><td>Strong CYP3A4 inhibitors may increase levels of ponatinib. Monitor concomitant therapy closely. </td></tr><tr><td><a href="/drugs/DB00175">Pravastatin</a></td><td>Boceprevir increases pravastatin AUC by 60% with boceprevir. Concomitant therapy should be closely monitored. </td></tr><tr><td><a href="/drugs/DB01045">Rifampicin</a></td><td>Strong CYP3A4 inducers will decrease levels of boceprevir. Concomitant therapy is contraindicated. </td></tr><tr><td><a href="/drugs/DB00877">Sirolimus</a></td><td>Boceprevir increases levels of sirolimus by affecting CYP3A4 metabolism. Concomitant therapy requires close monitoring. </td></tr><tr><td><a href="/drugs/DB01323">St. John's Wort</a></td><td>Strong CYP3A4 inducers will decrease levels of boceprevir. Concomitant therapy is contraindicated. </td></tr><tr><td><a href="/drugs/DB00864">Tacrolimus</a></td><td>Boceprevir increases levels of tacrolimus by affecting CYP3A4 metabolism. Concomitant therapy requires close monitoring. </td></tr><tr><td><a href="/drugs/DB00820">Tadalafil</a></td><td>Boceprevir increases levels by affecting CYP3A4 metabolism. Concomitant therapy is contraindicated. </td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><ul><li>Food increases the exposure of boceprevir by up to 65%. However, bioavailability is not affected and thus can be taken without regards to meals.</li></ul></td></tr></tbody></table>